Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of COX7A2 is associated with a good prognosis in patients with glioma

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Cytochrome c oxidase subunit 7A2 (COX7A2) is a nuclear-encoded polypeptide involved in assembly and regulation of cytochrome c oxidase (COX). Changes in the respiratory chain as big complex are known to be associated with cancer, but little research has been performed to discover COX7A2 as a prognostic marker in glioma. In the present study, we investigated COX7A2 expression and its prognostic significance in glioma. Glioma surgical tissue samples were taken from 126 patients who had been followed up from 4 to 51 months. Immunohistochemistry were used to test COX7A2 expression in the 126 tumor samples. Eighty-six of 126 (68.3%) paraffin-embedded glioma biopsies showed high expression of COX7A2. Statistical analysis displayed that there was significant difference of COX7A2 expression level in patients categorized according to WHO classification. Kaplan–Meier survival analysis revealed that patients with higher COX7A2 expression had longer overall survival time and better prognosis. R2: microarray analysis based on Tumor Glioma French 284 database, Tumor Glioblastoma TCGA 540 database, and Tumor Glioma Kawaguchi 50 database testified that high expression of COX7A2 is associated with a good prognosis in patients with glioma. Multivariate analysis showed that COX7A2 high expression was an independent prognostic indicator for survival. Our results suggest that COX7A2 could be served as a valuable prognostic marker of glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Das S, Marsden PA (2013) Angiogenesis in glioblastoma. N Engl J Med 369:1561–1563. doi:10.1056/NEJMcibr1309402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. doi:10.1056/NEJMoa1402121

    Article  Google Scholar 

  3. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S (2015) Mutational landscape and clonalarchitecture in grade II and III gliomas. Nat Genet 47:458–468. doi:10.1038/ng.3273

    Article  CAS  PubMed  Google Scholar 

  4. Wiestler B, Capper D, Sill M, Jones DT, Hovestadt V, Sturm D, Koelsche C, Bertoni A, Schweizer L, Korshunov A, Weiß EK, Schliesser MG, Radbruch A, Herold-Mende C, Roth P, Unterberg A, Hartmann C, Pietsch T, Reifenberger G, Lichter P, Radlwimmer B, Platten M, Pfister SM, von Deimling A, Weller M, Wick W (2014) Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 128:561–571. doi:10.1007/s00401-014-1315-x

    Article  CAS  PubMed  Google Scholar 

  5. Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693. doi:10.1007/s00401-015-1409-0

    Article  CAS  PubMed  Google Scholar 

  6. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. doi:10.1007/s00401-016-1545-1

    Article  PubMed  Google Scholar 

  7. Galati D, Srinivasan S, Raza H, Prabu SK, Hardy M, Chandran K, Lopez M, Kalyanaraman B, Avadhani NG (2009) Role of nuclear-encoded subunit Vb in the assembly and stability of cytochrome c oxidase complex: implications in mitochondrial dysfunction and ROS production. Biochem J 420:439–449. doi:10.1042/BJ20090214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Williams EG, Wu Y, Jha P, Dubuis S, Blattmann P, Argmann CA, Houten SM, Amariuta T, Wolski W, Zamboni N, Aebersold R, Auwerx J (2016) Systems proteomics of liver mitochondria function. Science 352:aad0189. doi:10.1126/science.aad0189

    Article  PubMed  Google Scholar 

  9. Wang L, McDonnell SK, Hebbring SJ, Cunningham JM, St Sauver J, Cerhan JR, Isaya G, Schaid DJ, Thibodeau SN (2008) Polymorphisms in mitochondrial genes and prostate cancer risk. Cancer Epidemiol Biomark Prev 17:3558–3566. doi:10.1158/1055-9965

    Article  CAS  Google Scholar 

  10. Simonnet H, Alazard N, Pfeiffer K, Gallou C, Béroud C, Demont J, Bouvier R, Schägger H, Godinot C (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23:759–768

    Article  CAS  PubMed  Google Scholar 

  11. Oppenheimer SR, Mi D, Sanders ME, Caprioli RM (2010) Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma. J Proteome Res 9:2182–2190. doi:10.1021/pr900936z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Elsner M, Rauser S, Maier S, Schöne C, Balluff B, Meding S, Jung G, Nipp M, Sarioglu H, Maccarrone G, Aichler M, Feuchtinger A, Langer R, Jütting U, Feith M, Küster B, Ueffing M, Zitzelsberger H, Höfler H, Walch A (2012) MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett’s adenocarcinoma. J Proteomics 75:4693–4704. doi:10.1016/j.jprot.2012.02.012

    Article  CAS  PubMed  Google Scholar 

  13. Aichler M, Elsner M, Ludyga N, Feuchtinger A, Zangen V, Maier SK, Balluff B, Schöne C, Hierber L, Braselmann H, Meding S, Rauser S, Zischka H, Aubele M, Schmitt M, Feith M, Hauck SM, Ueffing M, Langer R, Kuster B, Zitzelsberger H, Höfler H, Walch AK (2013) Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J Pathol 230:410–419. doi:10.1002/path.4199

    Article  CAS  PubMed  Google Scholar 

  14. Chrzanowska-Lightowlers ZM, Turnbull DM, Bindoff LA, Lightowlers RN (1993) An antisense oligodeoxynucleotide approach to investigate the function of the nuclear-encoded subunits of human cytochrome c oxidase. Biochem Biophys Res Commun 196:328–335

    Article  CAS  PubMed  Google Scholar 

  15. Wang HX, Zhao YX (2016) Prediction of genetic risk factors of atherosclerosis using various bioinformatic tools. Genet Mol Res 15:gmr7347. doi:10.4238/gmr.15027347

    Google Scholar 

  16. Lin CH, Liao CC, Huang CH, Tung YT, Chang HC, Hsu MC, Huang CC (2017) Proteomics analysis to identify and characterize the biomarkers and physical activities of non-frail and frail older adults. Int J Med Sci 14:231–239. doi:10.7150/ijms.17627

    Article  PubMed  PubMed Central  Google Scholar 

  17. Singh KK (2004) Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann N Y Acad Sci 1019:260–264. doi:10.1196/annals.1297.043

    Article  CAS  PubMed  Google Scholar 

  18. Johnson RF, Perkins ND (2012) Nuclear factor-kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends Biochem Sci 37:317–324. doi:10.1016/j.tibs.2012.04.002

    Article  CAS  PubMed  Google Scholar 

  19. Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, Bizzi A, Navarria P, Ascolese AM, Rudà R, Fernandes B, Pessina F, Grimaldi M, Simonelli M, Rossi M, Alfieri T, Zucali PA, Scorsetti M, Bello L, Chiti A (2017) Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging 44:1155–1164. doi:10.1007/s00259-017-3618-3

    Article  CAS  PubMed  Google Scholar 

  20. Babu R, Komisarow JM, Agarwal VJ, Rahimpour S, Iyer A, Britt D, Karikari IO, Grossi PM, Thomas S, Friedman AH, Adamson C (2016) Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. J Neurosurg 124:998–1007. doi:10.3171/2015.4.JNS142200

    Article  PubMed  Google Scholar 

  21. Theeler BJ, Yung WK, Fuller GN, De Groot JF (2012) Moving toward molecular classification of diffuse gliomas in adults. Neurology 79:1917–1926. doi:10.1212/WNL.0b013e318271f7cb

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Chen D, Rauh M, Buchfelder M, Eyupoglu IY, Savaskan N (2017) The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas. Oncotarget 8:51164–51176. doi:10.18632/oncotarget.17737

    PubMed  PubMed Central  Google Scholar 

  23. Wang HH, Chang TY, Lin WC, Wei K3, Shin JW (2017) GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. Sci Rep 7:8814. doi:10.1038/s41598-017-06851-3

    Article  PubMed  PubMed Central  Google Scholar 

  24. Maciaczyk D, Picard D, Zhao L, Koch K, Herrera-Rios D, Li G, Marquardt V, Pauck D, Hoerbelt T, Zhang W, Ouwens DM, Remke M, Jiang T, Steiger HJ, Maciaczyk J, Kahlert UD (2017) CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. Br J Cancer 117:102–112. doi:10.1038/bjc.2017.157

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by National Natural Science Foundation of China (81372692, 81472315, 81773290), National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2014BAI04B01), Science and Technology Program of Guangdong (2016A020213006), Natural Science Foundation of Guangdong Province (2014A030313167, 2017A030313497).

Author information

Author notes

  1. Shengze Deng and Yaomin Li have contributed equally.

Authors and Affiliations

  1. Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou Dadao Bei Street 1838#, Guangzhou, 510515, Guangdong, China

    Shengze Deng, Yaomin Li, Guozhong Yi, Bingxi Lei, Wei Xiang, Ziyang Chen & Songtao Qi

  2. Laboratory for Precision Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China

    Shengze Deng, Yaomin Li, Guozhong Yi, Bingxi Lei, Manlan Guo, Wei Xiang, Ziyang Chen, Yawei Liu & Songtao Qi

Authors
  1. Shengze Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yaomin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guozhong Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bingxi Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manlan Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ziyang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yawei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Songtao Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yawei Liu or Songtao Qi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study has been approved by the Ethics Committee of Southern Medical University and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 16 KB)

Supplementary material 2 (TIF 50259 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deng, S., Li, Y., Yi, G. et al. Overexpression of COX7A2 is associated with a good prognosis in patients with glioma. J Neurooncol 136, 41–50 (2018). https://doi.org/10.1007/s11060-017-2637-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2637-z

Keywords

Search

Navigation